The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Amid the deepest economic crisis since the Great Depression, it has been reported that startups overall face an "existential threat." But while life science startups have slimmer pickings than before, they stand to benefit from the industry's more conservative investment approach.
Steve Kafka, who joined Section 32 as a managing partner last fall, shared more about how the fund approaches investing across technology and healthcare. The company is currently raising $350 million for its third fund.
The VC firm, started by the former heads of Foundation Medicine and Google Ventures, is raising $350 million for its third fund, according to a filing with the Securities and Exchange Commission.
The company plans to triple its biomanufacturing R&D capacity beyond what it is currently and also develop new software programs. The company has more than 30 customers, ranging from startups to large firms.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company said it plans to expand into new supply chains for advanced therapeutics in addition to cell and gene therapies, as well as expanding its footprint in Europe and the Asia-Pacific region.
The startup, founded by a prominent health policy expert and a biotech industry executive, aims to bring down the cost of drugs by re-engineering and making less costly the process by which they are discovered and brought to patients.
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
With the funding, which came from Section 32, Eniac Ventures and Y Combinator, the company will advance its technology and add new employees to its sales and engineering teams.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It was a banner year for biopharma, with records broken in deal values, number of exited unicorns and the biggest-ever biotech IPO. But where do these unicorn valuations come from?
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.
BCBS Venture Partners leads round, with Section 32, Echo Health Ventures and others participating.
Michael Pellini, the featured speaker at MedCity's CONVERGE conference next month, holds forth on his new VC gig at Bill Maris-founded Section 32, the practice of oncology, and how healthcare must get more tightly integrated with tech.
Bill Maris, who cofounded GV (formerly Google Ventures) and led the firm from 2009 until earlier this year, is rumored to be setting up shop in San Diego with a new $230 million healthcare fund.